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ABSTRACT 
The mucosal membranes of the gastrointestinal, genitourinary and respiratory tract are the 
main targets for infection in the human body and are repeatedly challenged by pathogens. 
Passive immunization using delivery of antibodies at the mucosal membrane may thus 
provide a new first line of defense against these pathogens. 
The objective of this work was to genetically modify Lactobacillus, a natural inhabitant of 
the gastrointestinal tract, for in situ delivery of passive immunity against gastrointestinal 
infections. 
With the aim of identifying colonizing strains of Lactobacillus that could be used as 
vehicle for delivery of passive immunity in the gastrointestinal tract, a collection of ninety-
three Lactobacillus strains, derived from human fecal samples, was screened for markers 
for survival and persistence in the gastrointestinal tract (paper I). Five strains showed 
promising results and will be taken forward for testing of survivability in human gut and 
confirm their safety in human volunteers. 
A novel expression system for production and delivery of therapeutic molecules in 
Lactobacillus was constructed based on the framework of the apf gene from L. crispatus. 
This expression system was tested for delivery of antibody fragments both in a secreted 
form and cell wall anchored on the surface of the Lactobacillus. The expression cassettes 
were stably integrated on the chromosome using the integrase gene from the bacteriophage 
A2 to create “food grade” strains of Lactobacillus, devoid of antibiotic markers, for 
delivery of antibody fragments (paper II). 
The feasibility of delivering passive immunity against bacterial toxins in the 
gastrointestinal tract was tested with L. paracasei BL23 engineered to express a single 
chain antibody binding the anthrax protective antigen. The engineered Lactobacillus was 
able to provide protection in mice orally challenged with the anthrax edema toxin, 
validating the concept of in situ toxin neutralization in the gastrointestinal tract (paper III).  
Members of the family of Camilidae, to which llamas belong, express a subset of their IgG 
antibodies as heavy chain only antibodies. Their antigen binding domain is encoded in the 
single variable domain (VHH) that can be produced as a single polypeptide. The VHH has 
higher acid and proteolytic stability compared to conventional IgG making them ideally 
suitable for therapeutic use in the gastrointestinal tract. Llamas were immunized with the 
toxins A and B, the two causative elements of C. difficile associated diarrhea. A range of 
VHH neutralizing the dominant virulence factor, toxin B, were isolated and cloned for 
expression in L. paracasei. When expressed either in a secreted or cell wall anchored 
form, the Lactobacillus produced VHH were able to provide protection against the 
cytotoxic effects of toxin B. Prophylactic treatment with a combination of two strains of 
engineered L. paracasei expressing two toxin B neutralizing VHH could delay and 
provide partial protection against the effect of a toxin B producing strain of C. difficile in 
an in vivo hamster model (paper IV). 
In summary this work has shown the potential of using Lactobacillus for the delivery of 
passive immunity against gastrointestinal infections. Lactobacillus strains colonizing the 
gastrointestinal tract for delivery of antibody fragments could represent a potential new 
approach to management of the C. difficile associated diarrhea that could be used both 
prophylactically or for the prevention of recurrent infections. 
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1 INTRODUCTION 
 
1.1 LACTOBACILLUS 
Lactobacillus belong to the diverse group of Gram-positive lactic acid bacteria 
(LAB) defined by their ability to produce lactic acid as dominant metabolic end product 
of carbohydrate fermentation. Fermentation by LAB have for thousands of years been 
applied for the preservation of food components such as milk, meat and vegetables. 
Having not been associated with any pathogenic effects during this prolonged period of 
use, Lactobacillus have earned the status “generally regarded as safe” (GRAS) by the 
US Food and Drug Administration. Several species of Lactobacillus are natural 
residents of the gastrointestinal and vaginal tracts of vertebras. Due to their natural 
ability to thrive in the gastrointestinal tract and their close contact with the mucosal 
surfaces, Lactobacillus has been an obvious choice for direct in situ delivery of 
therapeutic molecules to the mucosa of both the gastrointestinal and vaginal tracts. 
1.1.1 Probiotic bacteria 
The human gastrointestinal microbiota constitutes a complex ecosystem that 
interacts symbiotically with its host. It is estimated that that it may consist of as many as 
1000 – 1200 species and contain up to 1014 microorganisms (1, 2). The greatest diversity 
and density is found in the distal part of the small intestine and in the colon where, for 
the colon, concentrations of up to 1012 CFU/ml of bacteria can be reached. The 
gastrointestinal microbiome has been attributed with several beneficial functions 
affecting the health of the host. This includes modulation of the immune response, 
antagonistic effects towards pathogens and interactions with host metabolism. The exact 
mechanisms and molecular basis for these effects are currently under investigation and 
slowly starting to be unraveled. 
Certain species of bacteria, isolated from the human microbiome or food products have 
been linked with the potential to excise these beneficial properties when applied 
therapeutically. They have been grouped under the term probiotic bacteria, defined as 
“live organisms which when administered in adequate amounts confer a health benefit 
on the host”. Three mechanisms of actions have been suggested for probiotics benefiting 
the health of the host (3, 4): (I) Improve the epithelial barrier function: by strengthening 
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the tight junction, induction of mucus or defensin production and by preventing 
apoptosis, (II) an antagonistic effect on pathogens: by production of antimicrobial 
compounds, competition for mucosal binding sites or nutrients, and by contributing to 
the gastrointestinal homeostasis, (III) modulation of the immune response and 
stimulation of the production of anti-inflammatory compounds. In the group of LAB, 
lactobacilli and bifidobacteria are the two species that have most frequently been 
associated with probiotic effects. Members of both groups are found in the human 
gastrointestinal microbiota and have the potential to transiently colonize the intestine 
when given orally (5, 6). Bioengineering of probiotic lactobacilli or bifidobacteria would 
potentially permit the combination of a probiotic effect and ability to colonize the 
gastrointestinal tract with an engineered therapeutic function. 
1.1.2 Expression systems 
Production of therapeutic molecules in Lactobacillus is generally directed 
towards either of three domains; the cytoplasm, anchored to the cell wall or secreted into 
the surrounding media. Which domain to target depends both on the produced molecule 
and therapeutic aim, but with proteins delivered to the cytoplasmic domain requiring 
bacterial lysis for their release to be effective. Comparative studies of the efficacy of the 
method of delivery have been carried out only in a few cases. One study, on the mucosal 
vaccination with L. plantarum producing a non-toxic fragment of tetanus toxin, 
surprisingly found that the cytoplasmic production yielded the strongest immunogenic 
response (7) but otherwise either cell wall anchored or secreted production are most 
frequently used (8). Secretion of recombinant proteins in Lactobacillus has been 
achieved using both homologous and heterologous signal peptides. Numerous signal 
peptides have been explored in attempts to optimize secretion of the therapeutic 
molecules but the efficacy of the signal peptides are highly variable and seems to 
dependent on the protein it is fused to (9-12), paralleling observations for secretion in B. 
subtilis (13, 14). Cell wall anchoring can be achieved through several different methods 
with the two most frequently applied being covalent binding or non-covalently binding 
using a domain interacting strongly with cell wall components. Covalent binding is 
mediated trough the sortase partway where a C-terminal anchoring domain containing 
the LPXTG binding motif is covalently bound to a cell wall displayed pentaglycine (15). 
For non-covalent, binding, several binding domains of cell wall displayed proteins have 
been used for the display of heterologous proteins on the cell wall including LysM (16), 
PsgA (17) and CbsA. 
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Despite the wider application of Lactobacillus for the delivery of therapeutic molecules, 
several challenges still exists to improve the delivery system. Currently, most delivery 
systems apply plasmid based expression vectors containing antibiotic markers.  For 
therapeutic expression, a stable food-grade chromosomal integrated expression system 
devoid of antibiotic markers would be required. A few integrative vectors for the 
construction of food grade expression systems have been developed to address this (18-
20). But often, a reduction in production of the therapeutic molecule is seen when going 
from expression from a multi-copy plasmid to a single copy of the gene chromosomally 
integrated. Optimization of the promoters would be one way to address this problem and 
increase the levels of production. Two approaches to this end have been the 
development of constitutive active promoters derived from ribosomal genes (21) as well 
as promoters that are transcriptional active in the gastrointestinal tract (22-24). In 
addition, the therapeutic use of engineered strains of lactobacilli will require a biological 
containment system to avoid release of the bacteria into the environment. For the clinical 
trial on the delivery of IL10 by L. lactis, a containment system was developed based on 
the insertion of the IL-10 gene into, and thereby deleting, the thyA gene, generating a 
thymidine autotroph. This strain relies on the supply of thymidine from the contents of 
the gastrointestinal tract but upon release into a less thymidine rich environment starts 
fragmenting its DNA using it as a thymidine source and eventually lyses and dies. This 
containment system was both validated in a pig model and in a subsequent human trial 
(25, 26). 
1.1.3 Therapeutic delivery 
Much of the initial work on the use of lactic acid bacteria for delivery of 
therapeutic molecules were focused on mucosal vaccination. This was driven by several 
advantageous properties of LAB for mucosal delivery; by residing on the mucosal 
surface they can induce both a mucosal and systemic immune response; they constitute a 
safe alternative to attenuated pathogens; their natural resistance to the gastrointestinal 
environment and in situ production of the antigen overcomes the problem with vaccine 
degradation when given orally; and lastly they can be engineered to express multiple 
antigens. The first study on the use of recombinant LAB for mucosal vaccination was 
carried out in 1990 with a strain of L. lactis producing a Streptococcus mutants surface 
antigen cell-walled anchored (27). Since then, numerous publications on the use of LAB 
for mucosal vaccination have been published, for review (28), with L. lactis based 
vaccines being developed against among others: Helicobacter pylori (29), Streptococcus 
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agalactiae (30) and Salmonella enterica (31). One of the most seminal studies on the 
use of LAB for therapeutic delivery was the engineering of L. lactis for delivery of IL-
10 for treatment of inflammatory bowel disease (IBD). Here the authors showed that 
delivery of murine IL-10, prevented the onset of colitis in IL10-/- mice and provided a 
50% reduction in colitis in mice treated with dextran sulfate (32). A subsequent phase I 
trial showed that L. lactis mediated delivery of IL-10 was safe in patients suffering from 
Crohn’s disease (CD) (26). The following phase II clinical trial though was a major 
setback, failing to show a statistical significant effect in patients with CD compared with 
the group receiving a placebo. Subsequently, several other studies on delivery of IL-10 
by L. lactis has shown effects in mouse models for airway inflammation (33), food 
allergy (34) and murine colitis (35) validating the strategy despite the negative results in 
the human clinical trial. Initially, due to the ease of engineering, much of the work on 
therapeutic delivery of biomolecules was carried out in L. lactis. Recently however 
additional genetic tools for the engineering of lactobacilli has become available and 
aided its use as vector for mucosal delivery. Lactobacilli, contrary to L. lactis, are 
natural habitants of the gastrointestinal tract and have the additional advantage of being 
able to temporarily colonize the small intestine and colon enabling prolonged delivery of 
therapeutic molecules. Limited studies have been carried out on the relative merits of the 
different bacteria as delivery systems and the choice of vector would likely depend on 
the therapeutic molecule in question. One study compared the induced immune response 
to a human papillomavirus antigen expressed cell wall anchored in both L. lactis and L. 
plantarum and found that immunogenicity was higher when expressed in L. plantarum 
(36). In this case the improved effect was suggested to arise from the ability of L. 
plantarum to persist at mucosal surfaces for several days. to date, Lactobacillus have 
been used to deliver a range of therapeutic molecules, including: antigens (37-39), 
antibody fragments (40, 41), anti-oxidants (42), cytokines (43), peptides (44), enzymes 
(45) and DNA molecules (46).  
1.1.4 Lactobacillus delivering passive immunity 
The ability of Lactobacillus to thrive and colonize the gastrointestinal tract 
suggests that they could be ideally suited for production of antibodies for passive 
immunity protecting the intestinal mucosa. The continuous in situ production of the 
antibody fragment would circumvent the need for the antibody preparation to pass the 
acidic environment of the stomach and a prolonged exposure to the proteolytic enzymes 
in the gastrointestinal tract. To date, lactobacilli have been applied for the delivery of 
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passive immunity in the oro-gastrointestinal tract against rotavirus, Streptococcus 
mutants, Porphyromonas gingivalis and Bacillus anthracis (40, 41, 47-50). Both scFv’s 
and VHH was used for passive immunization in these studies, but with the VHH 
fragment expressed much more efficiently than the scFv’s tested. The first study on 
delivery of passive immunity by engineered lactobacilli was conducted with a strain of 
L. zeae engineered for cell wall anchored expression of a scFv against the SAI/II 
adhesion molecule of Streptococcus mutants. Tested orally in a desalivated rat model, 
this strain could reduce the adherence of S. mutants leading to a significant reduction in 
caries. This verifying the potential approach, that has since been confirmed in several 
studies with L. paracasei expressing VHH directed against rotavirus in a mouse pup 
model of gastrointestinal infection (41, 51).  
1.2 ANTIBODIES FOR PASSIVE IMMUNITY 
Polyclonal antibody preparations have historically been used for oral delivery of 
passive immunity. With preparations of hyperimmune bovine colostrum (HBC) and 
chicken IgY used in most studies due to the high amount needed and the ease of 
purifying antibodies from these sources. Hyperimmune bovine colostrum is generated 
by immunizing cows during late pregnancy and will result in a more than a 100 fold 
increase in antibody titre. With the colostrum  yield being between 30 and 200 mg/ml of 
immunoglobulins of which approximately 75% is IgG1 (52). Chicken IgY is produced 
in the yolk of eggs, and the immunization of hens with only a small amount of antigen 
give high and long lasting IgY titres (up to 160 mg/egg) (53, 54). Despite both methods 
giving high yields of antigen specific antibodies, the cost of production is still high and 
antibody preparations varies in specificity from batch to batch. 
1.2.1 Monoclonal antibodies 
Antibodies as a modular defense system constitutes a central part of the immune 
system protecting the human body against infections by foreign objects like viruses and 
bacteria. They carry the ability to recognize a specific antigen unique to its target 
through their antigen binding sites, located on each tip of the “Y-shaped” structure. 
Immunoglobulin G is the most frequently used immunoglobulin for therapeutic 
applications and is also the principal component of immune globulin preparations used 
for intravenous delivered passive immunity (55). Human IgG is a heterotetramer 
consisting of two identical γ heavy chains and two identical light chains joined by 
disulfide bonds. Each light chain consists of one variable domain (VL) and one constant 
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domain (CL); while the heavy chains contain one variable domain (VH) and three 
constant domains (CH1, CH2, CH3). The N-terminal variable domains determine the 
specificity, affinity and the diversity of the antibody. Within each variable domain there 
are three hyper-variable regions (complementary determining regions, CDRs) 
responsible for antigen specificity and recognition by forming a tertiary structure 
complementing and binding the antigen. The role of the constant domains is to provide 
structural support for the antibody; determines the serum half-life of the antibody; and 
recruitment and activation of immune cells. Today approximately 30 mAb’s have been 
approved by the FDA therapeutic use in the United States (56, 57). 
Early attempts to produce full-length mAbs in prokaryotes were complicated by 
improper folding and aggregation of the polypeptides in the cytoplasm (58, 59). This 
was due to the complex structure of mAb’s with four separate peptide chains and 
multiple disulfide bonds needed to be formed to get the correct conformational folding. 
To overcome this, much attention has been directed towards expression of antibody 
fragments that consists of a single polypeptide chain but retains a binding diversity 
comparable to that of conventional antibodies. The most frequently used are the single 
chain fragment variable (scFv) antibodies and the variable domain (VHH) derived from 
camelid heavy chain only antibodies.  
1.2.2 Single chain antibody fragments 
Single chain antibody fragments are derived from mAb by fusing the two 
variable domains, variable light (VL) and variable heavy (VH) domains, with a flexible 
linker. This provides a single polypeptide that retains the antigen specificity of the mAb 
from which it was derived and potentially being capable of binding the antigen with an 
affinity similar to that of the parent mAb (60). The peptide linker joining the two 
fragments usually vary in length from 10 to 25 amino acids (aa), with 15 aa most 
frequently used. To avoid intercalation with the variable domains during folding, the 
linker should predominantly consists of hydrophilic aa (61). The decapentapeptide 
(Gly4Ser)3 linker is most frequently used but insertions of charged aa can be used to 
improve solubility of aggregating scFvs (62). The optimal linker length has been 
estimated to span at least 35 Å to permit free folding of the scFv (63) but by 
alternatively using short linkers of 10-12 aa, the scFv can be forced into a dimeric or 
trimeric conformation, increasing the valency of the scFv for improved functional 
affinity (64). 
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ScFvs exhibit a low degree of immunogenicity and their smaller size permits penetration 
into tissues inaccessible to full-size mAb (65). They are also easily amenable to 
engineering and can be cost effectively expressed both in prokaryotic and yeast 
expression systems. On the down side, the scFv lacks the multivalency of the mAb and 
have a short circulating half-life due to their small size as they are subjected to kidney 
clearance. Some scFvs also show reduced solubility as the detachment and refolding of 
the variable domains often exposes hydrophobic residues otherwise buried in the mAb, 
but this can be amended by engineering of the scFv. As a consequence of the scFv 
lacking the constant domains, both immune recruitment and effector functions are 
absent when used therapeutically. At the present stage, numerable scFvs have been 
expressed for a range of therapeutic and diagnostic applications (for review (66)). 
1.2.3 Heavy chain only antibody fragments 
One exception to the otherwise conserved structure of mammalian IgG is found in 
the species of Camelidae, to which camels, dromedary and llamas belong. In addition to 
the conventional IgG, the sera of Camelidae also contain two additional IgG subtypes, 
IgG2 and IgG3, devoid of the CH1 domain and light chain, but still retaining binding 
activity (67) (Figure 1). These heavy chain only antibodies are produced from a subset 
of immunoglobulin G heavy chain genes which due to a point mutation in a splice site, 
leading to a deletion of the CH1 domain (68, 69). The missing CH1 domain results in a 
failure to associate with the light chain and the heavy chain is secreted as a heavy chain 
only antibody. The binding specificity of these heavy chain antibodies is determined by 
the N-terminal variable domain, referred to as VHH (the variable domain of heavy chain 
antibodies). Within the VHH domain are four frame work regions (Fr) providing the 
core structure and three hypervariable regions, CDRs, involved in antigen binding. 
While the paratope of conventional IgG antibodies forms a flat surface or slight concave 
groove, highly suitable for binding to larger surfaces or linear peptides (70), the VHH 
domain on the contrary have a more pointing ellipsoid shape permitting it to insert into 
and bind to cavities on  
the surface of antigens (71), sites not accessible by conventional antibodies. Expressed 
on its own, the VHH domain of heavy chain antibodies is the smallest naturally 
occurring antigen-binding molecule known to date, with a molecular weight of only 12-
15 kDa. 
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Figure 1. Schematic representation of naturally occurring antibodies in sera of 
camelids: Conventional antibody (IgG1) and two types of homodimeric heavy-chain 
antibodies , IgG2 and IgG3. Also illustrated is the single chain fragment variable 
(scFv) derived from a conventional IgG1 and the variable fragment of heavy chain 
antibody (VHH). Reprinted with permission from (233). 
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VHH has, in many cases, been able to replace conventional antibodies both within 
therapeutic, diagnostic and biotechnological applications (57, 72). Several 
characteristics set the VHH apart from conventional antibodies and make them ideal 
candidates for therapies in the gastrointestinal tract. They are markedly more resistant to 
acidic conditions (and heat) due to their ability to refold after denaturation (73-75) and 
survives passage through the acidic environment of the stomach. In addition they can be 
easily engineered for increased resistance to both pepsin and chymotrypsin for extended 
half-life in the gastrointestinal tract (76, 77). Their size, stability, rapid clearance from 
blood and high degree of sequence identity with the human variable heavy domain gives 
them a low level of immunogenicity, a prediction that has been confirmed by the lack of 
immune response against intravenous injected VHH in both mice and humans (78-80). 
Lastly, they have proven to be highly suitable for production in bacterial expression 
systems due to their solubility, small size and single domain structure. 
1.3 PASSIVE IMMUNITY 
Active immunity is the process where the body reacts to exposure of an antigen 
and generates an adaptive immune response. The process constitutes the backbone 
against infections in vertebrates and contains a memory function so once an adaptive 
immune response is achieved, an antibody response can rapidly be mounted upon 
subsequent infections. The drawback is that the development of adaptive immune 
response can take days to weeks and in some cases, a protective adaptive immune 
response cannot be achieved. 
Passive immunity builds on the transfer of antibodies generated through the adaptive 
immune response, from one individual to another. Contrary to the adaptive immune 
response, passive immunity gives immediate protection, but the protection is short-lived 
and contains no “memory” of the infective agent to provide protection against future 
exposures. Passive immunity is classified either as natural or acquired depending on the 
method of antibody transfer. The transfer of maternal antibodies through the placenta to 
the unborn child generates a natural passive immunity that can protect the child for 
weeks to months after birth, giving the infant time to develop its own immune response. 
Acquired passive immunity on the other hand utilizes antibody preparations from 
immunized individuals (or animals) that are injected into a non-immune person to 
provide protection against a specific challenge. In both cases, the circulating antibodies 
only provide a transient protection for a couple of weeks to three or four months at most, 
as the antibodies successively are degraded. In addition to the systemic application, 
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passive immunity can also be applied directly to the mucosal surfaces to provide 
protection against infections. This occurs naturally in the transfer of maternal 
immunoglobulin from the naturally immunized mothers to the child through the 
colostrum and the milk during breastfeeding (81). Human breast milk contains secretory 
IgA against a range of enteric pathogens such as E. coli (ETEC), Salmonella, Vibrio 
cholerae, Campylobacter jejuni, Shigella and rotavirus (82-84). For therapeutic 
applications against enteric pathogens, a similar effect can be achieved by oral delivery 
of heterologous antibodies from immunized animals. 
1.3.1 Mucosal delivery of passive immunity in the gastrointestinal 
tract 
A large number of infectious agents enter the human body by breaching the 
epithelial barrier of the respiratory, gastrointestinal and genitourinary tracts. The 
mucosal immune system reacts by producing and secreting immunoglobulins as a first 
line of defense of the body against these infectious agents. Individuals with primary 
immunodeficiencies affecting immunoglobulin A are generally highly prone to both 
gastrointestinal and respiratory tract infections, illustrating the crucial role of antibodies 
in protecting the mucosal surfaces against infections. These observations support the 
concept of mucosal delivery of passive immunity for the protection against mucosal 
infections (85). 
Passive immunity against enteric pathogens has been explored for the last couple of 
decades. Despite this, no large scale application of oral delivered passive immunity has 
taken place. However, several different aspects of gastrointestinal infections and their 
treatment have kept it as an attractive approach, (I) an increasing emergence of strains of 
gastrointestinal pathogens with resistance to conventional antibiotics, (II) an observed 
reduced efficacy of vaccinations in the developing world and (III) a growing group of 
elderly with a decreased immune responsiveness suffering from gastrointestinal 
infections. 
For several gastrointestinal pathogens,  passive immunization has been successfully 
explored (like Escherichia coli, Helicobacter pylori, Rotavirus and Clostridium difficile) 
using primarily bovine colostrum and chicken IgY derived antibody preparations.  
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1.3.1.1 Escherichia coli 
Escherichia coli is a Gram-negative facultative anaerobic bacteria belonging 
to the normal gastrointestinal microbiota of both humans and animals. The majority of 
E. coli strains are commensals and colonize the lower intestine. Several pathogenic 
strains causing diarrheal diseases exist and are divided into six different pathotypes 
based on their virulence properties (86); with three of the non-invasive pathotypes being 
the enteropathogenic E. coli (EPEC), enterohaemorrhgic E. coli (EHEC) and 
enterotoxigenic E. coli (ETEC). Second to rotavirus, ETEC is regarded as one of the 
major diarrheal pathogens causing up to 400 million diarrheal episodes and more than 
300,000 deaths annually among preschool children in the developing world (87). ETEC 
is non-invasive but causes a profuse watery diarrhea by producing one or both of two 
enterotoxins, heat-labile enterotoxin (LT) and heat-stable enterotoxin (ST). 
The traditional use of antibiotic for management of diarrhoeagenic E. coli is becoming 
increasingly difficult with strains of ETEC and EPEC progressively gaining resistance to 
commonly used antibiotics. For EHEC, the use of antibiotics is not recommended for 
treatment of the infection as it induces the production of Shiga toxins (Stx-1 and Stx-2), 
aggravating the infection (88) and potentially triggering hemolytic-uremic syndrome 
(HUS). 
One of the main indicators for a role of passive immunity in the management of 
diarrhoeagenic E. coli infections, arise from the fact that secretory immunoglobulins in 
breast milk protects newborns against ETEC and EPEC (89). Studies on the use of 
immunoglobulin preparations from cows and chickens immunized with EHEC, ETEC 
and EPEC have been shown to be an effective prophylactic treatment against infection 
in farm animals (90-92). In humans, infant feeding formulas supplemented with milk 
immunoglobulin concentrate (MIC) containing antibodies to EPEC has been shown to 
be efficient in treating EPEC infections in infants (93). In another study, hyperimmune 
bovine milk antibody preparations raised against purified colonization factor antigens 
was shown to provide protection in volunteers challenged orally with ETEC (94). on the 
contrary one randomized, placebo controlled study, on children infected with 
diarrhoeagenic E. coli, using a preparation of bovine immunoglobulin concentrate (BIC) 
from cows hyperimmunized with EPEC and ETEC, showed no significant therapeutic 
effect (95). A difference that could arise from variations in the properties of the antibody 
preparations. Further studies, using intraperitoneal injections of monoclonal antibodies 
neutralizing the cytotoxic effect of Shiga toxins, have also been shown to be effective in 
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reducing diarrhoeagenic EHEC infection both in mice and in a gnotobiotic piglet model 
(96-98). 
1.3.1.2 Rotavirus 
Rotavirus is the most common cause of severe diarrhea in infants and young 
children worldwide. With gastroenteritis caused by rotavirus leading to between 55,000 
to 70,000 hospitalizations per year in the United States (99) and an estimated 500,000 
deaths per year, primarily in the developing world  (100). Two vaccines against 
rotavirus are currently licensed (RotateqTM and RotarixTM) and have showed high 
efficacies (>85%) in reducing episodes of severe diarrhea when used in developed 
countries (101, 102). Recent trials conducted in the developing world with the most 
pressing need for protection have had been less efficient with an efficacy ranging from 
39.3 % (RotateqTM tested in Sub-Saharan Africa) and to 61.2% (RotarixTM tested in 
South Africa and Malawi) (103, 104).  
Studies using monoclonal antibodies against the viral coat proteins, VP4 and VP7, have 
shown that virus infection can be inhibited by blocking the cellular attachment of the 
virus (105) and by inhibiting decapsidation of the virus (106). Passive immunization has 
been explored in several studies using either HBC or hyperimmunized chicken yolk 
immunoglobulins and have shown protection in both animal models and human clinical 
trials. (85, 107-111) Recently a number of anti-rotavirus VHH fragments with protective 
effects have been developed through immunizations of llamas (112, 113), with the aim 
of bringing down the cost of treatment. One of these VHH fragments (ARP1) has, as a 
further development of the passive immunization strategy against rotavirus, been cloned 
both for expression in Lactobacillus (41) and rice (114) for direct delivery in the 
gastrointestinal tract. 
1.3.1.3 Clostridium difficile 
Clostridium difficile is a gram positive, sporeforming , anarobic bacterium and 
the primary  cause of antibiotic associated diarrhea in the hospital setting (for details see 
section 5). The primary virulence factors and the causative elements of the diarrhea are 
the two endotoxins toxin A and toxin B and for passive immunity, much of the focus has 
been directed towards neutralization of these toxins. Passive immunization by either 
subcutaneous or intraperitonal injection of neutralising antibodies against these two 
toxins have been shown to prevent the mortality caused by C. difficile infection in a 
hamster model (115, 116). Despite recent evidence suggesting that toxin B is the 
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dominant virulence factor (117) and the one causing the disease in this model, other 
studies have shown that antibodies against both toxins are usually needed for complete 
protection (116, 118). In humans, similar studies with antibodies directed against both 
toxins have been shown to be able to resolve the symptoms in patients with C. difficile 
infections (119, 120). Recently, two toxin neutralizing human MAbs directed against the 
receptor binding domain of toxin A and toxin B have been developed (116). Tested in a 
phase II clinical trial, a single infusion (10 mg/kg bw) of these two antibodies given in 
combination with metronidazole or vancomycin could significantly reduce the rate of 
recurrent infection with C. difficile (121). Currently, these antibodies have been taken 
forward and are currently undergoing phase III clinical trials for their use for passive 
immunization against recurrent C. difficile infections. Less work has been carried out on 
the use of oral delivery of passive immunity against C. difficile. This is possibly due to 
the large doses of antibody fragments required and the prolonged period of 
administration needed to prevent relapse of infection. However, oral delivery of passive 
immunity has though been tested using bovine-enriched whey from cows immunized 
with either whole C. difficile cells or the toxins only and were shown to be able to 
prevent the relapse of C. difficile infections following antibiotic therapy (121-123). The 
knowledge that the C. difficile toxins rely on attachment to a cellular receptor displayed 
on the epithelial cells for cellular uptake suggests that blocking of toxin binding to the 
receptor could effectively prevent the cytotoxicity of the toxins. Experiments with oral 
delivery of both chicken IgY and bovine antibodies against toxin A and toxin B have 
been shown to be protective in a hamster model and that this strategy is possible (118, 
124-126). 
1.3.2 Summary 
In summary the delivery of passive immunity to the mucosa of the 
gastrointestinal for the treatment of infections has shown promising results for a range of 
pathogens. For several of the pathogens, the data is indicative and better characterized 
antibody preparations targeting specific virulence factors could be needed to show the 
real potential of the approach. Large-scale studies on the therapeutic effects also still 
need to be carried out to evaluate the efficacy of the strategy. For oral delivery, this is 
likely hampered by the large doses needed for these studies and the costs associated with 
the production of these but by addressing these issues, the potential of passive 
immunization of the gastrointestinal mucosa could be realized. 
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1.4 BACILLUS ANTHRACIS 
Anthrax is caused by the bacterium Bacillus anthracis, a Gram-negative spore 
forming bacteria. The disease is still endemic in some parts of the world, primarily 
among herbivores in less-developed countries, but can affect a range of species, 
including humans. Anthrax and the management of anthrax infections though mostly 
remain in focus due to its status as one of the most prominent bioterrorism threats. The 
spores of Bacillus anthracis are the transmissible factor in the spread of the disease and 
is ranked as one of the leading bioweapons due to their stability, high lethality and ease 
of dispersion (127). Immunization, either passive or active, is central in countering the 
effects of the anthrax toxins and safe guarding against the development of strains 
resistant to antibiotics. 
1.4.1 Anthrax infections 
Anthrax infections fall into three different categories, reflecting the route of 
entry; inhalational, gastrointestinal or cutaneous in order of severity of the infection. 
With regard to bioterrorism, the most realistic mode of mass exposure includes 
inhalational or gastrointestinal infections. Conceptually, the idea of targeting the food 
supply is not new (128) and a few records of planned use of anthrax spores for 
deliberately targeting the oral route exist (129, 130). Relatively little is however known 
about the physiopathology of gastrointestinal anthrax, despite it being prevalent in 
ruminant livestock. Initial infection is established in the Peyer’s Patches throughout the 
small intestine, eventually leading to systemic infection by spreading to the draining 
jejunal lymph nodes, the spleen and, finally, the lungs. Gastrointestinal infection by B. 
anthracis preferentially occurs after abrasions in the mucosa but can also occur in the 
absence of damage in which case infection propagation is slower (131). Natural 
occurrence of human gastrointestinal anthrax in the western world is rare due to the high 
standard of the food supply chain but is more common than inhalational anthrax in the 
developing world (132).  
1.4.2 Anthrax toxins 
The pathogenesis of B. anthracis is due to three plasmid encoded (pXO1) 
toxicity genes; pagA (PA), lef (LF) and cya (EF) forming a tripartite protein complex, 
causing the lethal symptoms associated with anthrax. The protective antigen (PA) 
combines with the lethal factor (LF) and edema factor (EF) to form the lethal toxin (LT) 
and edema toxin (ET) respectively (133). PA is the component affording binding to  
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  Figure 2. Molecular mechanism of action of anthrax toxin. Protective antigen 83 
kDa in size (PA83) binds either TEM8 or CMG2 at the cell surface and is processed 
to PA63 by PCs such as furin. PA63 heptamerizes, allowing it to bind EF and/or LeF. 
The complex formed is endocytosed and subsequent acidification of the endosome 
leads to translocation of the bound EF and/or LeF. Once in the cytosol, EF catalyzes 
the formation of cAMP from ATP and LeF mediates the proteolytic cleavage of 
MKKs, which disrupts the mitogen-activated protein kinase (MAPK) pathway. 
Reprinted with permission from (253). 
Kasper Krogh Andersen 
16 
either of two receptors, the tumor endothelial marker 8 (TEM8) and the capillary 
morphogenesis 2 (CMG2) (134) (figure 2). The receptor bound PA is proteolytically 
activated, facilitating oligomerization of PA into a heptameric prepore structure, forming 
the binding sites for LF and EF. The complete toxin complex is endocytosed and, upon 
acidification of the early endosome, the prepore undergoes conformational change 
whereby LF and EF are translocated into the cytosol (for review see (135)). LF is a 
metalloprotease cleaving MAPK (mitogen-activated protein kinase) kinases (136), 
inactivating MAPK signaling pathways and inducing an atypical vascular collapse in 
mice (137). EF is a calmodulin-dependent adenylate cyclase which increases cyclic 
AMP levels in cells and induces extensive intestinal fluid accumulation and 
hemorrhaging lesions (138, 139). Both active and passive vaccination strategies against 
anthrax have previously been attempted and directed primarily towards inactivation of 
the toxin components, where PA is the dominant immunogen, and several neutralizing 
antibodies binding to epitopes blocking the binding to its receptors have previously been 
developed (140, 141).  
1.4.3 Treatment 
B. anthracis is sensitive to a range of antibiotics including amoxicillin, 
ciprofloxacin, doxycycline, levofloxacin and penicillin (142). However, the window of 
opportunity for treatment is limited as antibiotics are only effective on the bacteria and 
not blocking the continuous action of the anthrax toxins. Once symptoms of toxemia 
have started, antibiotics will have a limited effect as stand-alone treatment (143, 144). 
Currently, there is one vaccine available for the treatment of anthrax in the US, 
BioThrax, which is a recent improved version of the Anthrax Vaccine Adsorbed (AVA). 
Current indications suggest that only three priming doses will generate immunity after 6 
months, compared to the 6 doses and 12- 18 months for immunity with the previous 
version of AVA. Due to the time frame, costs and possible side effects, therapeutic 
treatment is generally considered most cost effective (145, 146). 
Therapeutic treatment for anthrax infection is based on antibiotic use, post exposure 
vaccination and anti-toxin antibodies, with a combinatorial approach of rapid post 
exposure vaccination combined with antibiotics treatment being the most promising 
(147). 
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1.4.4 Anti-toxin antibodies 
Antibodies against the anthrax toxins is one of the most promising areas for 
increasing the treatment window post infection as well as counteracing the toxemia from 
strains resistant to antibiotics. Currently, a range of therapeutic antibodies are under 
clinical development with ABthraxTM (148, 149), an IgG1 mAb against PA, having 
been approved for treatment of inhalation anthrax. Delivery of passive immunity by 
monoclonal antibodies direct targeting the toxin components is a feasible strategy, as 
results from the AVA vaccine have indicated that anti-PA antibodies are critical for the 
immunity to anthrax (150-152). Monoclonal antibodies against the anthrax toxins are 
also under development, targeting each of the three toxin components; PA, EF and LF 
(153, 154). 
1.5 CLOSTRIDIUM DIFFICILE, A GASTROINTESTINAL PATHOGEN 
Clostridium difficile is an anaerobic Gram-positive endospore forming bacteria 
belonging to the phylum Firmicutes. It is the primary cause of nosocomial infections in 
the western world (155) and the main cause of  antibiotic-associated  
pseudomembranous colitis (156). The spectrum of disease can range from antibiotic 
associated diarrhea to severe pseudomembranous colitis that can be fatal (157, 158). The 
bacterium was identified in 1935 as part of the gut flora of neonates (159) and first 
described as a cause of antibiotic associated diarrhea in 1978 (160-162). Initially the 
infections were regarded as mild side effects of antibiotic use (157) but over the years 
both the frequencies and the severity of the infections have increased to the state where 
CDI is regarded as a serious threat to the health care settings with high rates of 
morbidity and mortality (163), reaching an estimated treatment costs in excess of three 
billion USD and causing more than 14,000 deaths in the USA alone in 2012, according 
to the Center of Disease Control and Prevention. This rising challenge has been 
attributed to a more widespread use of antibiotics and an increased virulence of strains 
of C. difficile encountered in hospitals. 
1.5.1 Infection and disease progression 
The spores of C. difficile are shed by infected individuals and found throughout 
the environment with a wide distribution in healthcare settings. Spores are taken up by 
ingestion through contact with contaminated surfaces. During the gastrointestinal 
passage, germination receptors are activated and the dormant spore begins its vegetative 
growth cycle and commence colonization when they reach the anaerobic environment of 
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the cecum and colon (164). Of the patients colonized with C. difficile in hospitals, only 
between one third to half of the individuals develops a C. difficile infection (CDI), with 
the remaining becoming asymptomatic carriers (165, 166). Asymptomatic carriage is 
found in up to 7 - 17 percent of hospitalized patients (167, 168) and has been attributed 
to the spread of C. difficile, by functioning as a reservoir for infection. Previously, C. 
difficile was predominantly considered a hospital-acquired infection but recently, 
community-acquired CDI is also on the rise with infection now commonly being 
identified in populations previously considered low risk, including children, young 
adults and people with no health care exposure (169, 170). 
The predominant risk factor for acquisition of CDI is the use of antibiotics, with up to 20 
percent of antibiotic associated diarrhea being caused by CDI (171, 172). The highest 
rate of infection is found concurrent or during the first month following treatment, but 
an elevated risk of acquiring CDI exists for up to three months after cessation of 
antibiotic therapy (173). CDI is directly linked with the use of broad spectrum 
antibiotics which destabilizes the gastrointestinal flora and permits the colonization of C. 
difficile. Other risk factors for acquiring CDI include long-term hospitalization, 
advanced age and immune suppression (172). 
Recurrent infections are common and one of the major challenges in treatment of CDI. 
With studies showing that 33% of patients get re-infected after the first CDI episode and 
of these, 45% will experience even a third or multiple rounds of infection (174). It has 
been suggested that it may relate to an inability of the host to restore an optimal gut flora 
(175, 176) or that strains of C. difficile have developed mechanisms to persist in the 
gastrointestinal tract despite antibiotic treatment (177). 
1.5.2 Clostridium difficile toxins 
The two toxins, toxin A and toxin B, have though since long been established as 
the causative virulence factors for Clostridium difficile associated disease (CDAD). At 
least one of the two toxins is required for the pathogenicity of CDI but their individual 
contribution to the disease is still debated. In clinical isolates, strains giving rise to 
CDAD have either been toxin A-B+ or toxin A+B+. No disease causing strains have to 
date been isolated that were toxin A+B-, highlighting the role of toxin B in the disease. 
Recent studies with engineered toxin deletion strains tested in a hamster model have also 
suggested toxin B as the dominant virulence factor but with conflicting data on whether 
toxin A can induce the disease on its own (117, 178, 179). The role of a third toxin, the 
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binary toxin, in CDI was for long debated but recent understanding of its mode of action 
and role in epidemiology have highlighted its importance for the pathogenicity of C. 
difficile (180). 
Toxin A and toxin B 
The toxicity of C. difficile primarily arises from two main virulence factors, toxin A 
(tcdA, 308 kDa) and toxin B (tcdB, 269 kDa), both being large single-subunit exotoxins 
which share extensive homology (for review see (178)). Both have a modular domain 
structure with a N-terminal enzymatic domain, a central translocation domain and a C-
terminal receptor binding domain. The binding domain, consisting of repetitive 
oligopeptides, is responsible for the initial binding to epithelial cells and induces toxin 
uptake through receptor mediated endocytosis (Figure 3). Upon lowering of the 
endosomal pH, the central domain exposes a hydrophobic membrane insertion domain 
that inserts and translocates the N-terminal catalytic domain from the endosome to the 
cytosol. The N-terminal enzymatic domain encodes a cysteine protease that, through 
autocatalytic cleavage, releases the domain from the endosome to the cytosol. The 
released N-terminal glucosyltransferase domain glycosylates the host GTPases in the 
cytosol, leading to alterations in the actin cytoskeleton, disruption of barrier functions 
and apoptosis (181). This results in an inflammatory response and degradation of the 
intestinal epithelial cell layer. The genes for tcdA and tcdB are both encoded within the 
19.6 kb pathogenicity locus (PaLoc) together with regulatory genes for their expression; 
the negative regulator tcdC and the positive regulator tcdR. 
Binary toxin 
The binary toxin, CDT, is produced in approximately 10 % of C. difficile strains. It 
belongs to the family of clostridial iota-like toxins and consists of two components (182, 
183). The enzymatic component, a ribosyltransferase encoded by the cdtA gene and the 
binding component encoded by the cdtB gene. The cellular uptake of the binary toxin 
follows a mechanism similar to the protective antigen (PA) mediated uptake of the 
anthrax toxins. With the binding component (CDTb), after binding to the cell surface 
receptor, LSR, undergoes proteolytic activation and forms a heptameric structure that 
mediates the uptake and release of CDTa in the cytosol (for review (184)). After 
translocation into the cytosol, CDTa ADP-ribosylates actin resulting in complete 
destruction of the actin cytoskeleton of the cells and uncontrolled growth of  
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Figure 3. Molecular mechanism of action of TcdA and TcdB. The toxins 
bind to the surface of enterocytes through the receptor-binding domain and 
are endocytosed. Acidification of the endosome leads to translocation of the 
enzymatic domain and the CPD into the cytosol. Cytosolic IP6 then binds to 
the CPD, thus activating it and initiating autoprocessing. The released 
enzymatic domain catalyzes the transfer of a glucose moiety to a conserved 
threonine residue on Rho/Ras proteins, which inhibits downstream signaling 
events. Reprinted with permission from (253). 
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microtubules. This creates long membrane protrusions on the epithelial cells that 
increase the adherence and colonization of C. difficile (185, 186). 
1.5.3 Hypervirulence 
Since 2004, a dramatic increase in both the severity and number of cases of CDI 
has been noted. This was initially linked to a PCR ribotype 027 strain 
(FT027;BI/NAP01) that caused severe outbreaks with increased mortality in both North 
America and Europe. The RT027 strain together with RT078, were identified as 
examples of new hypervirulent strains posing a mounting challenge to the management 
of CDI. The cause of the increased virulence of these strains has since been studied in 
detail. 
Multiple factors have been assigned as possible hypervirulent factors in attempt to 
understand and develop methods to contain these strains. Initially, the hypervirulence of 
RT027 were linked to an abrogative mutation in the repressor gene, tdcC, leading to 
increased levels of toxin A and B being produced (187). However subsequent studies 
failed to find the link between tdcC deletions and toxin levels (188, 189). The binary 
toxin has also been attributed to the increased severity of the hypervirulent strains (190-
192), but its presence in non-epidemic strains complicates this conclusion (193). In 
addition, increased sporulation frequencies (194) and resistance to fluoroquinolones 
(195) have been suggested as factors increasing the virulence but again, this notion has 
been disputed by others (196). Overall, the picture remains complicated and it is likely 
that there are multiple factors contributing to the increased virulence of these strains. 
1.5.4 Treatment of Clostridium difficile infections 
The primary treatment for CDI is, like the causative element, antibiotics combined 
with rehydration therapy. The two most common used antibiotics are metronidazole and 
vancomycin. With the current European guidelines recommending the use 
metronidazole for non-severe CDI and vancomycin for severe and recurrent CDI. Cure 
rates of 73 - 94 percent for patients treated with metronidazole and 84 - 94 percent for 
those treated with vancomycin has been reported in a recent systematic review 
comparing the effectiveness of antimicrobials for the treatment of CDI (197). Recently, 
a new narrow spectrum antibiotic, Fidaxomicin, has been approved for treatment of 
CDI. It targets a narrow spectrum of Gram-positive bacteria and is minimally absorbed 
from the gastrointestinal tract. Fidaxomicin has shown comparable effectiveness as 
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vancomycin but patients experience significantly lower rates of recurrent infection (198, 
199). This effect has been attributed to the preservation of the microflora due to its 
narrow spectrum of activity (200). 
Fecal transplantation has over the last couple of years emerged as one of the promising 
new treatments against CDI. It builds on the observation that the disruption of the 
microbiome is central to the onset of the disease and aims at restoring the colonic flora 
by transplanting a liquid suspension of intestinal bacteria from a healthy donor. Fecal 
transplantation has proven highly effective in reducing the recurrencies of CDI that has 
otherwise been difficult to manage. A systematic review including data on 317 patients 
with recurrent CDI showed a 92 overall success rate with 89 percent of the patients 
responding after a single dose (201). 
The use of probiotic bacteria for the treatment of CDI builds on the concept of 
stabilizing the gut flora with the aid of beneficial microbes. A recent meta-analysis on 
the use of probiotics for the treatment of CDI found that the use of probiotics can 
prevent CDAD but not for C. difficile infections in patients receiving antibiotics (202). 
Others have proposed that a multi-strain probiotic, resembling the human microbiota, 
would be most efficient for treating CDAD (203). Overall, a multitude of studies have 
been carried out but the evaluation of the efficacy has to some extend been hampered by 
the use of different probiotic strains and study design and to date the verdict is still out 
and the approach controversial (204). 
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2 AIM 
 
2.1 GENERAL AIM 
The aim of this work was to explore the possibilities for using Lactobacillus as a vehicle 
for delivering passive immunity against gastrointestinal bacterial infections. 
 
2.2 SPECIFIC AIMS: 
 
Paper I: To screen and characterize human derived Lactobacillus with the aim of 
identifying strains that can be used as vectors for delivery of therapeutic molecules in 
the gastrointestinal tract. 
 
Paper II: The development of a food grade expression system for production and 
delivery of antibodyfragments in the gastrointestinal tract.  
 
Paper III: To construct a strain of Lactobacillus expressing single chain antibody 
fragments against the Bacillus anthracis protective antigen as a model system for 
gastrointestinal toxin neutralization. 
 
Paper IV: To engineer L. paracasei BL23 for the expression of toxin neutralizing single 
domain antibodies as a therapeutic strategy against C. difficile associated diarrhea. 
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3 MATERIALS AND METHODS 
3.1 BACTERIAL STRAINS AND GROWTH CONDITIONS 
E. coli DH5α (Invitrogen, Carlsbad, CA) was grown in LB media at 37°C with 220 rpm 
orbital shaking or on LB-agar plates at 37°C. Lactobacilli were grown in lactobacilli 
MRS broth (Difco, Sparks, MD) at 37°C without agitation or anaerobically on MRS-
agar plates (BD - GazPak EZ, Sparks, MD). Antibiotics were added at the following 
concentrations when indicated: ampicilin (100 μg/ml) and erythromycin (300 μg/ml E. 
coli and 5 μg/ml lactobacilli).  
Construction of recombinant Lactobacillus Strains 
Three expression plasmids, (pAF100, pAF400 and pAF900) were utilized for 
therapeutic expression of antibody fragments in the current studies. Directing the 
expression towards secreted, secreted and attached or cell wall anchored display 
respectively. For construction of plasmids please se detailed description in paper II. The 
DNA fragment containing the antibody fragment for cloning into the expression 
plasmids was excised using NcoI and NotI restriction enzymes (Promega) and ligated 
into the NcoI/NotI digested Lactobacillus expression vectors, pAF100, pAF400 or 
pAF900.  The correct sequence of the expression cassette was verified by sequencing. 
The expression plasmids were transformed into L. paracasei BL23 (previously known 
as L. casei or L. zeae ATCC 393 pLZ15-  (246)) by electroporation as previously 
described [23,33]. Thereby, generating the Lactobacillus strains expressing the antibody 
fragment either anchored, secreted or attached. For detailed description of how the 
respective constructs were generated please consult the respective papers where 
complete lists of plasmids generated also can be found. 
3.2 EXPRESSION ANALYSIS 
Western Blot 
The transformants were grown in MRS with 5 μg/ml erythromycin until an OD600 of 
1.0. The cultures were centrifuged at 3,200 × g to separate the pellet from the 
supernatant. The supernatant was filter sterilised, pH adjusted to 7.0, dialysed against 10 
mM Tris (pH 8.0) and concentrated using Amicon Ultra-4 centrifugal filter units (10 
kDa cut off, Millipore, Carrigtwohill, Co. Cork, Ireland). The concentrated supernatant 
was mixed with 2 × Laemmli buffer and boiled for 5 minutes (min). The cell culture 
pellet was washed twice with PBS, resuspended in 100 μl Laemmli buffer and boiled for 
5 min. The cell extract was centrifuged at 16,000 × g to remove cell debris and the 
supernatant containing soluble proteins was kept. The supernatant and cell extract were 
run on a 10% SDS-polyacrylamide gel at 170 volts and the proteins were transferred 
onto a nitrocellulose membrane (Hybond-ECL, GE Healthcare, Little Chalfont, 
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Buckinghamshire, UK). The membrane was blocked with PBS-T (PBS with 0.05% (v/v) 
Tween 20 + 5% (w/v) milk powder) and successively incubated with mouse anti-E-tag 
antibodies (1 μg/ml, GE-Healthcare) and HRP (horse radish peroxidase) labelled goat 
anti-mouse antibodies (DAKO A/S, Glostrup Denmark). The signal was detected by 
chemiluminescence using the ECL Plus™ Western Blotting detection system (GE 
Healthcare).  
Enzyme-Linked ImmunoSorbent Assay (ELISA) 
96 well microtiter plates (EIR/RIA plate, Costar, Lowell, MA) were coated with 100 μl 
antigenat 1 μg/ml in PBS overnight (o/n) at 4°C. Plates were subsequently blocked with 
200 μl 1% BSA (in PBS containing 0.05% Tween 20, PBS-T) for two hours at 4°C. 
After washing with PBS-T, dilutions of Lactobacillus culture supernatants were added 
and the plates incubated at 4°C o/n. Plates were subsequently washed three times and 
100 μl mouse anti-E-tag antibody (GE-healthcare) was added (1 μg/ml) in blocking 
solution, followed by incubation at room temperature for 2 h. Plates were then washed 
three times in PBS-T and incubated with 100 μl AP conjugated rabbit anti-mouse 
antibody at 1/1000 (Dako A/S, Glostrup Denmark) in blocking solution. Following an 
additional 1 hour incubation at room temperature, the plates were washed twice in PBS-
T and once in PBS, resuspended in 100 μl of diethanolamine buffer (1M, pH 10.0) 
containing 1 mg/ml pNPP (Sigma-Aldrich, St. Louis, MO) and absorbance was read 
after 10-30 min at 405 nm in a Varioskan Flash (Thermo Scientific, Waltham, MA). 
General protocol, for variations see respective papers. 
Flow cytometry 
50 μl of Lactobacillus cultures grown to an OD600 of 1.0 in MRS were harvested by 
centrifugation (8000 rpm, 1 min) and washed three times in PBS. Bacteria were 
resuspended in 50 μl PBS with 1% BSA (PBS-BSA) and incubated for 30 min on ice 
sequentially with 50 μl anti-E-tag antibody (10 μg/ml) and 50 μl FITC conjugated anti-
mouse immunoglobulins (diluted 1/100) (Jackson Immunoresearch Laboratories, West 
Growe, PA), all diluted in PBS-BSA. Bacteria were washed with 500 μl PBS between 
all both incubations. Samples were resuspended and fixed in 300 μl 2% 
paraformaldehyde in PBS and analysed using a FACS Calibur machine (Becton 
Dickinson, Franklin Lakes, NJ). Protocol for detection of antibody fragments on the 
bacterial surface. For other protocols please consults respective papers. 
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3.3 PHENOTYPIC TESTING 
Auto-Aggregation  
Auto-aggregation assay was performed according to Pascual et al. (247) with certain 
modifications. Lactobacilli were grown for 48 h at 37°C on MRS agar (Oxoid) plates in 
microaerobic environment (10% CO2). A loopful (10 μl) of culture was suspended on a 
glass microscope slide in 1 ml of 0.9% saline solution (pH 6.7) to a final concentration 
that corresponded to McFarland Nephelometer Standard 3. Auto-aggregation was 
determined as the ability to form aggregates (clearly visible sand-like particles) within 2 
min at room temperature. The results were expressed as: score 0, no auto-aggregation; 
score 1, intermediate auto-aggregation (presence of some flakes); and score 2, strong 
auto-aggregation. 
Acid, Bile and Pancreatin Tolerance 
The effect of low pH, bile, and pancreatin on the survival of lactobacilli was examined 
in microwell plates (Costar® 96 Well Cell Culture Clusters, Myriad Industries, San 
Diego, CA). MRS broth (Oxoid) was adjusted to a pH range between pH 5.0 and pH 2.0 
to test acid tolerance and contained oxgall (2% w/v) (Sigma, Steinheim, Germany) and 
pancreatin (0.5% w/v) (Sigma) to test bile and pancreatin tolerance. Each 180-μl volume 
of adjusted and non-adjusted MRS broth (as control; pH 6.0) was inoculated with 20 μl 
of suspension of lactobacilli (McFarland 1.0 turbidity standard) and incubated in 
microaerobic environment at 37°C for 4 h. The number of cells in the suspension of 
lactobacilli (CFU ml−1) and the number of surviving cells following incubation in pH-, 
bile- and pancreatin-adjusted media was determined by plating 100 μl of tenfold serially 
diluted sample onto the MRS agar (228, 247). Strains with viable cell counts equal to 
viable counts before incubation in pH-, bile- and pancreatin-adjusted media were 
considered as resistant to a particular pH, bile and pancreatin concentration. 
Antibiotic Susceptibility 
Minimum inhibitory concentrations (MICs) of 13 antibiotics were determined by E-test 
method. Wilkins-Chalgren (Oxoid) agar plates with 5% horse blood, E-test antibiotic 
strips (AB Biodisk, Solna, Sweden) and 48 h of incubation at 37°C in an anaerobic 
glove chamber were applied. The breakpoints were determined in accordance with the 
CLSI guidelines for gram-positive microorganisms as follows: ciprofloxacin and 
rifampicin (4 μg ml−1); erythromycin (8 μg ml−1); ampicillin, imipenem, gentamicin 
and tetracycline (16 μg ml−1); cefoxitin, cefuroxime, vancomycin, chloramphenicol and 
metronidazole (32 μg ml−1); and trimethoprim-sulfamethoxazole (4/76 μg ml−1). 
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Haemolytic Activity 
A single line of lactobacilli culture (grown in MRS broth (Oxoid) for 48 h) was streaked 
onto blood agar plates containing either human or horse blood. Haemolysis was 
evaluated following 24 and 48 h of incubation in aerobic, microaerobic (10% CO2) and 
anaerobic (90% N2, 5% CO2, 5% H2) environment. One Staphylococcus aureus strain 
(ATCC 25923) and two Streptococcus pyogenes strains (ATCC 19615 and a human 
clinical isolate) were used as positive controls. 
3.4 PROTEIN PURIFICATION 
scFv’s purifification see paper III 
VHH fragment purification se paper IV 
Toxin fragments purification se paper IV 
3.5 IN VITRO PROTECTION ASSAYS 
Macrophage toxicity assay to assess neutralisation by scFvs 
Protection by Lactobacillus and E. coli produced scFvs were analysed by their capacity 
to protect the J774 MΦ cell line from killing by LT (248). Briefly, J774 MΦ were added 
to 96-well, flat-bottom wells (5 × 104 MΦ/well) and incubated at 37°C in 5% CO2 in air. 
After 12 hours of incubation, LT (i.e., 1 μg/ml rPA and 1 μg/ml LF, (List labs)) pre-
mixed with scFvs were added to the cultures and incubated for an additional 12 hours. 
Viable MΦ were evaluated by colorimetric assay by reading absorption at 562nm after 
addition of Methylthiazolyldiphenyl-tetrazolium bromide (MTT) (Sigma-Aldrich)  
(249). MTT was used at a concentration of 5 mg/ml, and a volume of 20 μl (100 
μg/well) was added to individual wells.  
C. difficile In vitro toxin neutralization assay 
Neutralization of toxin A and toxin B by anti-toxin VHH was analyzed on the MA-104 
cell line that have previously been characterized for sensitivity to C. difficile toxin A and 
toxin B. Toxin A and toxin B (List Biological laboratories) were titrated on cell line 
before use to adjust for batch variations and used at a 2-4 fold the killing dose unless 
otherwise stated. MA-104 were seeded at 1x105 cells per well in a 96 well microtitre 
plate and incubated for 24 hours at 37°C, in 5% CO2 in DMEM GlutaMAXTM 
(Dulbecco's Modified Eagle Medium) (Life Technologies, Grand Island, NY) with 10% 
BFS (bovine fetal serum) reaching 70 – 80 % confluence. Toxin A and toxin B were 
mixed with VHH at varying concentrations in sera free DMEM and incubated on ice for 
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45 min. Cells were washed with serum free DMEM and overlaid with 100 µl 
VHH/toxin mix and incubated at 37°C for 24 hours in 5% CO2. Cytotoxic effect of non-
neutralized toxins was scored microscopically as beginning to complete cell rounding. 
Complete toxin neutralization was characterized as visually undamaged cells.  
Toxin neutralization by llama sera were tested in fourfold sera dilutions (1/100 – 
1/12800) incubated with 10 ng/ml toxin B and 50 ng/ml toxin A. The sera-toxin mixes 
were overlaid on washed MA-104 cells and toxin neutralization scored as presence of 
undamaged cells after 24 hours incubation as described above. 
Adsorption of toxin B by Lactobacillus cell wall displayed VHH was carried out by 
incubating twofold serial dilutions of Lactobacillus in DMEM (8x109 to 1.25x108 
CFU/ml) with a fivefold cytotoxic dose of toxin B (50ng/ml) under mild agitation at 
37°C for one hour. Prior to incubation, Lactobacillus were washed three times in 
DMEM with 25mM hepes buffer to bring pH to 7.2. The DMEM buffer was 
supplemented with 50 units/ml of penicillin, 50 µg/ml streptomycin and 25 µg/ml 
gentamicin (all from Lifetechnologies, Grand Island, NY) to avoid bacterial growth. 
Lactobacillus and adsorbed toxin B were pelleted by centrifugation at 12000 rpm for 5 
minutes and 100 µl of supernatant was transferred to each well of a microtitre plate with 
washed MA-104 cells. Cytotoxicity of the remaining toxin B in the adsorbed 
supernatant was recorded as described above. 
3.6 IN VIVO MODELS 
Mouse safety model (Paper I) 
The animal trial was approved by the Ethic Committee on Animal Experiments of the 
Ministry of Agriculture of Estonia. Ten BALB/c mice (Scanbur BK AB, Sweden) were 
fed a mixture of six Lactobacillus strains (with each freshly cultured strain being present 
at a concentration of 107 CFU per daily dose) in their drinking water for 5 consecutive 
days. Throughout the trial, the animal’s activity, behaviour and general health were 
observed daily. Five randomly selected mice were sacrificed on Day 5, and the other 
five mice on Day 15. Samples for histological and microbiological analyses were 
collected. 
For histological analysis, tissue sections of liver, spleen, kidney and lungs of the 
sacrificed mice were fixed in 10% of formaldehyde and embedded in paraffin. The 
samples were stained with haematoxylin and eosin, and by using van Gieson method. 
Alterative and inflammatory changes in tissues were evaluated. 
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For microbiological analysis, heart blood (10 μl) and homogenized tissue of liver, 
spleen, kidney and lungs were plated onto blood agar and MRS agar (Oxoid). After 72 h 
of incubation in aerobic (blood agar plates) and microaerobic environment (MRS 
plates), colonies were enumerated and lactobacilli identified. Lactobacillus strains were 
typed by using arbitrarily primed polymerase chain reaction (AP-PCR) with three 
different primer sets: ERIC1R (5′-ATG TAA GCT CCT GGG GAT TCA C-3′) and 
ERIC2 (5′-AAG TAA GTG ACT GGG GTG AGC G -3′) (6), primer 5′-ACG CGC 
CCT-3′ (7) and primer 5′-ATG TAA CGC C-3′ (8). 
In vivo neutralization of anthrax toxins (Paper III) 
Female C57BL/6 mice, six-seven weeks of age, were obtained from Jackson 
Laboratories (Bar Harbor, ME). Mice were maintained under specific pathogen-free 
conditions and provided food and water ad libitum. All studies were performed in 
accordance with both National Institutes of Health and Institutional guidelines and 
approved by the Ohio State University Institutional Animal Care and Use Committee 
(Protocol number 2009A0210).  
A dose study of the oral effect of ET was carried out on groups of mice challenged with 
10, 25, 50 and 100 μg of ET (equal amount of rPA plus EF (List Labs)) given in 100 μl 
PBS by gavage. After 16 hours, the toxic effect was measured as ET induced fluid 
accumulation in the small and large intestine. Mice were euthanized with CO2 and death 
confirmed by cervical dislocation prior to removal of small and large intestine. Fluid 
accumulation was measured as percent of the weight of the small and large intestine 
compared to total body weight.  
The KKA307, KKA308, KKA317 and L. paracasei pAF400 (3) strains were grown in 
MRS to an OD600 of 1.0, harvested by centrifugation and resuspended in culture 
supernatant with pH adjusted to 7.0 to give 5 × 109 cfu/ml. Nine-twelve weeks old 
C57BL/6 mice (body weight 15-20 g) were given 2.5 × 109 cfu recombinant 
Lactobacillus by gavage. Four hours later they were challenged with a non-lethal dose 
of 50 μg ET (50 μg rPA plus 50 μg EF (List Labs)) together with an additional 2.5 × 109 
cfu recombinant Lactobacillus by gavage. After 16 hours, the toxic effect of the ET was 
measured as fluid accumulation in the small and large intestine.  
Prophylactic hamster model (Paper IV) 
Six weeks old male Syrian Golden hamsters were obtained from Harlan laboratories 
UK. Hamsters were housed individually under specific pathogen free conditions with 
commercial diet, R-70 (Lactamin, Sweden), and water ad libitum. Studies were 
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conducted according to guidelines of University of Tartu and approved by the Ethic 
Committee on Animal Experiments of the Ministry of Agriculture of Estonia. 
Hamsters were treated with a single orogastric dose of clindamycin (30 mg/kg bw, 
Sigma Aldrich) to destabilize the intestinal flora 24 hours before a challenge by 103 
spores of a toxin A-B+ strain of C. difficile 630 (9). Prophylactic treatment with yeast 
produced anti-toxin B VHH started on the same day as clindamycin treatment and was 
continued for a total of seven days. One group of hamsters (n=6) received a mixed dose 
of 125 µg af each of the three yeast produced toxin B neutralizing VHH fragments 
(VHH-B2, VHH-G3 and VHH-D8) twice daily by gavage. The two control groups (n=6 
each) received either 375 µg of an irrelevant anti-rotavirus VHH twice daily or no VHH.  
In an identical prophylactic model, hamsters received Lactobacillus expressing cell wall 
anchored anti-toxin B VHH twice daily by gavage. The Lactobacillus strains KKA413, 
KKA416 and KKA101 were grown in MRS (Oxoid, UK) to an OD600 of 1.0, harvested 
by centrifugation and washed twice in PBS. Three groups of hamsters (n=6) received, 
by gavage, either: (I) twice daily 5x109 CFU of each of the two strains of L. paracasei 
BL23 (KKA413 and KKA416) expressing the VHH-B2 and VHH-G3 cell wall 
anchored respectively; (II) twice daily 1x1010 CFU of a non-expressing strain of L. 
paracasei BL23 (KKA101) or (III) spores only.  
 Hamster activity, behavior and general health, including diarrhea and mortality were 
evaluated for the duration of the experiments. The hamster model was terminated on day 
five after the spore challenge to comply with the ethical permit and surviving hamsters 
sacrificed with cervical dislocation. Autopsy on sacrificed hamsters was performed 
under sterile conditions using a class II microbiological safety cabinet (Jouan, France). 
For full protocol please consult paper IV 
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4 RESULTS AND DISCUSSION 
 
Several of the criteria that have been outlined for characterization of new probiotic 
strains concerns viability, persistence and safety of the bacteria in the gastrointestinal 
tract. These traits would also be desirable for strains of Lactobacillus used to deliver 
passive immunity, as it would ensure a stable and persisting delivery system. In paper I, 
ninety-three human isolates of Lactobacillus, isolated from the fecal samples of Swedish 
and Estonian children, were characterized for markers of colonization, tolerance to 
gastric conditions, antibiotic resistance and potential adverse effects. 
 Aggregation is a marker that has frequently been used as an indicator of adhesive ability 
(205-207) prior to running assays on epithelial cells or mucosal sections. Fifty-five of 
the strains (59%) had an auto-aggregative ability with thirty of these being strongly 
aggregative. Strains with a positive aggregation profile were chosen as a basis for the 
seventy–six strains taken forward for tests on tolerance to gastric conditions. The 
remaining twenty-two strains were included from the facultative heterofermentative 
(FHEL) and obligatory heterofermentative (OBEL) lactobacilli to increase the diversity 
of the strains to and even out the number from the respective fermentative groups. 
Nearly all strains tolerated high bile concentrations (2.0 % w/v) and all were unaffected 
by high levels of pancreatin (0.5 % w/v), reflecting their gastrointestinal origin. Half the 
strains also tolerated incubation for up to four hours at a pH 3.0 or less as a test for 
resistance to gastric passage. Twenty four strains were taken forward for testing for 
antibiotic susceptibility, primarily based on aggregation profile and resistance to low pH 
as the two other markers provided little discrimination among the strains. 
The selected strains were tested for resistance against 13 commonly used antibiotics. All 
of the tested Lactobacillus showed an intrinsic resistance to metronidazole and the 
majority of the strains were resistant to cefoxitin (14 of 24 strains), vancomycin (12 
strains), ciprofloxacin (13 strains), and trimethoprim-sulfamethoxazole (16 strains). This 
is similar to what has previously been reported and could suggest a high natural 
resistance towards these antibiotics (208, 209). Plasmid-encoded erythromycin, 
tetracycline and chloramphenicol resistance has been reported in lactobacilli and are a 
reason for growing concern (210-212). Based on a phenotypic test it is not possible to 
confirm the presence or absence of transferrable resistance genes as the origin of the 
antibiotic resistance. However, a high level of resistance that is not shared within the 
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species should be a reason for worry and warrants further studies of the origin of 
resistance. One strain of L. buchneri showed resistance to tetracycline and was excluded 
from further studies. The issue of antibiotic resistance within probiotic strains is two 
sided. The general notion is that strains with antibiotic resistance located on mobile 
elements should be avoided when selecting probiotic strains, both to avoid the risk of 
transfer of resistance to gastrointestinal pathogens, but also as antibiotic treatment would 
be the safeguard against, however rare, translocation of probiotics resulting in adverse 
effects. However, in cases where the resistance is through mutations or intrinsic 
resistance mechanisms, these strains could potentially aid the re-colonization of the gut 
after antibiotic treatment due to their natural resistance to the used antibiotic. 
Antagonistic effect towards pathogens is often a parameter when selecting prospective 
probiotic strains. In this study, this was not analyzed as the primary objective was to 
select strains that could be used for therapeutic expression against multiple targets. A 
previous screen on strains used in this study have shown that individual strains inhibited 
growth of potential gastrointestinal pathogens (213). For optimal therapeutic effect 
against a specific pathogen, a desirable synergistic effect could possibly be achieved by 
using a strain with antagonistic activity as vector for delivery of the therapeutic 
molecules. 
To test the strains for their capacity for storage, the ten strains with the highest overall 
score in the previous tests were subjected to lyophilisation. Six strains, L. gasseri 
E16B7, L. gasseri 177, L. paracasei 317, L. paracasei 1-4-2A, L. fermentum 338-1-1 
and L. acidophilus  821-3, all yielding at least 1010 CFU/g, were taken forward for 
safety studies in mice as the last parameter of selection. 
 Oral administration for five days with a mixed dose of the six strains (107 CFU/day of 
each) caused no adverse effects on the general health and activity of the treated mice. 
The heart blood, liver, kidney and lung samples obtained by autopsy on day five all 
showed no translocation of the lactobacilli. For one mouse, the spleen culture was 
positive and showed growth of both L. paracasei and L. plantarum. The L. paracasei 
was confirmed to be the strain 1-4-2A and this strain was thus discarded due to its 
potential for translocation. For the L. plantarum isolate, the AP-PCR typing showed no 
similarity to the fingerprint patterns of any of the six strains and had likely originated 
from the indigenous flora of the mouse. Generally, translocation of probiotic 
Lactobacillus in humans is rare and in the cases it does occur, the effects are rarely 
detrimental. Due to a long history of safe use, Lactobacillus has earned a status as 
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GRAS for consumption. However health damaging effects have been observed in some 
immunocompromised patients and suggests caution when selecting strains for 
therapeutic use (214). This highlights a duality where some probiotics have been shown 
to improve the barrier function (215-217) whereas others, in the case of underlying 
disease, have shown an ability to translocate (214). 
The five final strains from the screening described here were taken forward to a second 
step where they were tested for safety and persistence in the gastrointestinal tract of 
human volunteers (218). 
       The production and delivery of therapeutic components by engineered lactobacilli is 
to a large extent dependent on the expression system applied. Several criteria need to be 
met for an expression system for optimal delivery of therapeutic proteins in the 
gastrointestinal tract: flexible targeting of proteins, high level of expression, lack of 
antibiotic markers and stable expression. In paper II, a flexible expression system that 
facilitates chromosomal integration was developed for expression of antibody fragments 
and delivery of passive immunity. The expression system was based on the 
transcriptional framework of the aggregation-promotion factor (apf) gene from L. 
crispatus M247 (219). The apf gene encodes a cell surface gene attached non-covalently 
to the cell wall (220) that was initially thought to be connected with aggregation (221) 
but later shown to be involved in maintenance of cell shape (222). A series of 
translational fusions with a scFv antibody fragment against the SAI/II adhesion of 
Streptococcus mutants and the apf gene was constructed to optimize the level of 
expression, secretion and localization of the scFv. Eight constructs were made with the 
apf gene together with an additional three constructs including a C-terminal PrtP 
anchoring domain (40) (For details see paper II). 
Three constructs, pAF100, pAF400 and pAF900 resulted in markedly different 
localization, with the scFv being produced as a secreted protein, a covalently cell wall-
anchored protein or both secreted and cell wall-attached protein respectively. These 
constructs were selected for delivery of passive immunity in subsequent studies. The 
choice of delivery and display for therapeutic molecules from lactobacilli depends to a 
vide extent on both the target and the nature of the therapeutic molecule. For delivery of 
passive immunity, both secreted and cell wall anchored display of antibody fragments 
have been applied. The majority of the studies have used a cell wall anchored display 
which has been shown to be successful against rotavirus (VHH) (41, 51) and 
Streptococcus mutants (scFvs and VHH) infection (40, 47, 50). For secreted production, 
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functional scFvs have been produced in Lactobacillus against rotavirus (41, 49) and HIV 
(223) but the only secreted antibody fragments tested in an animal model so far, a VHH 
against rotavirus, failed to provide protection (41). Both methods of delivery should 
have the potential to deliver a passive immunity but at the moment only cell wall-
anchored display have been functional in vivo. 
For therapeutic applications, chromosomally integrated expression constructs are 
considered a prerequisite. The primary reason is to reduce the risk of horizontal transfer 
of either the antibiotic marker or the recombinant gene. In addition, it also significantly 
improves the stability of the expression constructs and obviates the need for either 
antibiotic of autotroph markers to maintain the plasmid in the Lactobacillus. To generate 
stable food grade strains devoid of antibiotic markers, the expression cassettes were 
inserted into the chromosome of L. paracasei BL23 using the phage A2 integrase (paper 
II). In a subsequent step, the non-food grade DNA, including the antibiotic marker, was 
excised using a β-recombinase, leaving only the integrated expression cassette on the 
chromosome. The strain with the chromosomally integrated cassette producing surface 
anchored VHH (ARP1) (L. paracasei EM233) was shown to be stable for more than 50 
generations. A significant improvement compared with previous studies where a 
secreted scFv produced from the non-integrated plasmid pAF100 were lost after 15 
generations upon removal of the antibiotic pressure (unpublished data). One of the 
challenges with chromosomal integrated constructs is the significant reduction in 
expression that can be expected when going from a multi-copy plasmid to a single 
chromosomally integrated gene (224). In the present study, only a 6 to 10 fold reduction 
in expression of the anchored and secreted construct was observed when integrated on 
the chromosome which is significantly less than expected considering that the pAF 
plasmids are derived from a the high copy number plasmid, pIAV7 (162 copies/cell) 
(225). However, it is highly likely that expression from a strong promoter, like the apf 
promoter, will encounter several bottlenecks within translation, secretion and anchoring 
of the proteins and therefore do not benefit from copy number in a linear fashion. Most 
important, the level of ARP1 antibody fragment displayed in L. paracasei EM233 was 
sufficient for the modified lactobacilli to reduce infection when tested in an animal 
model of rotavirus infection. The protection level was similar between the 
chromosomally-integrated and plasmid expression systems validating the use of the 
chromosomally-integrated system for subsequent applications. 
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Oral challenge with the toxins of Bacillus anthracis was chosen to explore the 
possibility of delivering passive immunity by engineered Lactobacillus against toxins in 
the gastrointestinal tract. Targeting the protective antigen (PA) of B. anthracis with 
antibodies, as a mean to prevent the assembly and uptake of the toxin complexes, 
neutralizes effectively both the lethal factor and the edema factor. Deriving single chain 
antibodies from neutralizing monoclonal antibodies is a way to obtain antibody 
fragments suitable for expression in bacterial expression systems. 
Here, a dual strategy was applied using both a previously characterized scFv, 1H scFv, 
with neutralizing activity against PA of B. anthracis (226) as well as a scFv constructed 
from a neutralizing anti-PA mAb. The fusion of the VH and the VL from the anti-PA 
mAb with a decapentapeptide (Gly4Ser)3 linker generated a scFv that could be expressed 
both secreted and anchored in Lactobacillus (data not shown). The mAb derived scFv 
could be displayed but bound with very low affinity towards PA compared to the mAb 
from which it was derived. This illustrates a commonly encountered problem when 
constructing a scFv from mAb, that despite maintaining the binding specificity, the scFv 
often has a reduced affinity compared to the parent mAb. This is primarily due to 
difficulties to obtain the correct conformational folding and stability of the scFv once the 
variable domains are removed from the structural support provided by the constant 
domains. Improvement of the affinity can be obtained by either mutational evolution or 
grafting the antigen specificity onto a variable domain framework providing better 
stability and folding (227). The other anti-PA scFv, developed through molecular 
evolution of a scFv with lower affinity (226), showed good high affinity when expressed 
in L. paracasei BL23 and was chosen as the basis for the rest of the work. 
 The scFv was cloned into the three previously constructed expression vectors for 
expression as a secreted protein, a cell wall anchored protein or a secreted and attached 
protein (referred to as attached construct). All three constructs directed the scFv to the 
expected cellular location and showed binding to PA. For secreted production, the 
highest level of scFv was found in the supernatant of the construct producing the scFv in 
the attached form which had three times higher levels than the secreted construct. This 
construct utilizes a non-covalent anchor and a significant proportion of the scFv is found 
in the supernatant, possibly due to either shedding from the cell wall or saturation of the 
binding sites. For the cell wall binding, both the anchored and attached construct 
displayed the scFv on the bacterial surface. 
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 In vitro neutralization was tested with purified scFvs from the supernatant of the 
secreting and the attached construct. Both were able to protect macrophages from the 
cytotoxic effects of anthrax LT. The secreted scFv provided the best protection with 
only a 3.5 fold molar excess needed for complete for neutralization of the LT. The 
attached scFv needed a slightly higher dose, a 5-10 fold molar excess, to confer 
protection against the LT. This corresponds with the ELISA data, where a 3-fold higher 
production of the scFv in the supernatant of the secreted and attached construct shows a 
binding that is comparable to the secreted construct. This suggests that the secreted 1H 
scFv might have a slightly higher binding affinity than the 1H scFv produced from the 
attached construct. 
The in vivo protection of three constructs was tested in a mouse model of prophylactic 
protection against an oral challenge with the B. anthracis edema toxin. Anthrax edema 
toxin causes a significant fluid accumulation in the small and large intestine leading to a 
10-15% increase in total intestinal weight. The three expression constructs provide a 
choice for the mechanism of neutralization 1; anchored and attached scFv constructs 
immobilizing PA on the cell wall of the lactobacilli and clearing of bound PA from the 
intestinal tract by gastric emptying 2; secreted scFv expression as seen both using the 
secreted construct and the attached construct where a significant proportion of the scFv 
are non-cell wall attached, leading to diffusion of the neutralizing scFvs in the 
gastrointestinal lumen with subsequent binding and inactivation of PA. Mice treated 
with either L. paracasei BL23 expressing the 1H scFv in either anchored or secreted 
form failed to show any significant difference in fluid accumulation when compared to 
mice receiving only ET. For mice treated with L. paracasei BL23 expressing the 1H 
ScFv in the attached form, the intestinal weight was in the same range as the negative 
control and significantly lower compared to mice receiving ET only (P<0.05). These 
results indicate that attached scFv can prevent the uptake of the ET in the intestine by 
blocking the binding of the ET complex to the receptor. The reason that the attached 
construct provided protection when the secreted and anchored showed no significant 
effect, remains to be elucidated. In this case, it is particularly interesting as three 
constructs are producing the same anti-PA scFv and are transcribed from the same 
promoter. One explanation might be the dual function of the attached construct where 
the scFv is both cell wall displayed and secreted into the supernatant. The secreted part 
of the 1H scFv produced by the attached construct would have an unbound cell wall 
attaching domain, allowing it to re-attach to the cell wall of lactobacilli after binding to 
PA. This could theoretically provide a therapeutic advantage as the resident lactobacilli 
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in the gastrointestinal microbiota could function as a binding reservoir for the attached 
1H scFv, mopping up and immobilising PA. We have shown in this paper that the re-
attachment of the 1H scFv to L. paracasei is indeed possible, but further studies would 
be needed to determine if this is a parameter involved in the neutralization seen with the 
attached construct. Homologous binding domains are also found in several other Gram-
positive bacteria so re-attachment could hypothetically involve other members of the 
gastrointestinal flora (219, 228). The protection by engineered L. paracasei expressing 
high affinity scFv against PAin the gastrointestinal tract provides an indication that 
infections with toxin producing gastrointestinal pathogens could be targeted 
successfully. 
 
C. difficile is one of the most prominent toxin producing gastrointestinal pathogen 
and represents an obvious target for delivery of passive immunity against bacterial 
toxins. C. difficile produces two exotoxins, toxin A and toxin B, which are the causative 
elements of C. difficile associated diarrhea. Only one non-neutralizing scFv targeting 
toxin B has previously been produced (229). To generate neutralizing antibody 
fragments against both toxin A and toxin B, two llamas were immunized with 
inactivated toxin A and B. For both llamas, a good humoral response against both toxins 
were seen when testing the post immune sera at day 28. Two VHH specific phage 
libraries were constructed from the pooled peripheral blood lymphocytes and 
subsequently panned for toxin binding VHH. The isolated VHH showing best binding to 
either of the toxins were tested for their capacity to neutralize toxin in a cell based in 
vitro assay. Through several rounds of selection, four VHH neutralizing toxin B were 
isolated, VHH-B2, VHH-E2, VHH-G3 and VHH-D8. For the toxin A, fifteen unique 
anti-toxin VHH were isolated and tested in the in vitro neutralization assay. For all 15 
VHH, a leaky protective effect were seen where the toxin was slowly released over time 
leading to killing of the cells. This transient protection could indicate that the binding 
affinity of the selected VHHs were either too low to compete with the toxin receptor or 
that not all of the relevant epitopes for preventing toxin processing were blocked. 
Interestingly, recent work on the receptor binding domain of toxin A has begun 
illuminating the structural base for C. difficile toxin neutralization. This work, conducted 
with anti-toxin A VHH fragments suggests that multiple epitopes on the receptor 
binding domain of toxin A are involved in toxin binding and neutralization (230). Two 
distinct epitopes were identified, with one of the epitope potentially repeated up to seven 
times in the highly repetitive structure of the toxin A receptor binding domain. Slight 
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sequence variations in the repeated epitope suggest that multiple antibodies could be 
needed for complete neutralization, an observation that helps to explain previous 
observations that using a mix of several antibodies binding to both non-overlapping and 
overlapping epitopes of toxin A can improve neutralization (231, 232). In the present 
study, no improvement in the toxin  neutralization could be seen when using 
combinations of up to 11 of the selected anti-toxin A VHH, pointing again to the VHH 
either having too low binding activity or not blocking the relevant epitopes. It still leaves 
the question why no neutralizing VHH could be isolated despite that a high sera toxin 
neutralization titer was found in the llamas. One possible explanation could be the 
mixed composition of the llama sera with heavy chain only antibodies constituting 10-
25 percent of the total IgG and conventional IgG making up the rest and providing the 
neutralization observed (233). Successful isolation of toxin A neutralizing VHH are 
possible though, as shown by a previous study, but could require a different 
immunization strategy, using for example only the receptor binding domain of toxin A 
for immunization (232). 
However, several neutralizing anti-toxin B VHH were isolated and showed strong 
neutralizing activity against the dominant virulence factor, toxin B. The protective 
concentration of these for neutralizing 20 ng of toxin B in vitro ranged from 80-320 
ng/ml to 5.12 µg/ml, which corresponds to 55-220 fold molecular excess of VHH to 
toxin B for complete neutralization by the best neutralizing VHH, VHH-G3. This 
protective range is comparable, or better, than previously isolated therapeutic anti-toxin 
B HuMAb tested for neutralization in a similar assay (116), suggesting that the anti-
toxin B VHH isolated in the present study could be suitable for therapeutic use.  
The anti-toxin B VHH were cloned into the previously constructed expression plasmids 
for both secreted and cell wall anchored expression. The four VHH showed good 
expression with three of the four VHH (VHH-E2, VHH-G3 and VHH-D8), secreting 
between 1-2 µg/ml of VHH which is around 10-20 fold higher than what we generally 
can achieve with well-expressed scFv (234), illustrating the advantage of VHH for 
therapeutic expression in Lactobacillus. 
Mapping of the four best neutralizing anti-toxin B VHH on the purified domains of 
toxin B revealed that all four bound to the cell wall binding domain thereby indicating 
that their neutralizing effect most likely arises by blocking the toxin binding to the 
receptor and preventing cellular toxin uptake. This is in line with previous observations 
that many C. difficile neutralizing antibodies appear to be directed towards the receptor 
Lactobacillus mediated targeting of gastrointestinal pathogens 
 39 
binding domain of the toxins despite immunizations having been conducted with the full 
length toxins (116, 118, 235-237). From a passive immunity perspective, antibodies 
binding to the receptor binding domain are desirable as they would prevent uptake of the 
toxin and the neutralized toxin would thus remain in the colon to be eliminated together 
with the feces. 
Both the secreted and the cell wall anchored VHH expressed from Lactobacillus could 
provide protection in the in vitro neutralization assay, validating that the engineered 
strains were warrant testing in a hamster model of CDI. 
A prophylactic oral treatment model was chosen for the current study as it would be the 
most likely application for Lactobacillus mediated toxin neutralization for treatment 
against C. difficile infection. Syrian golden hamsters were challenged with spores of a 
toxin A-B+ strain of C. difficile 24hours after disruption of the indigenous flora with 
clindamycin.  
To establish the efficacy of toxin neutralization, the model was initially tested with a 
mixture of the three best in vitro neutralizing VHH (VHH-G3, VHH-D8 and VHH-B2), 
produced and purified from yeast. Surprisingly no protective effect was seen despite that 
high levels of anti-toxin B VHH were given continuously during the treatment (375 ug 
twice daily). The hamsters succumbed to the infection at the same rate as the control 
groups receiving either an irrelevant VHH preparation or C. difficile spores only. 
To test if the lack of protection seen with the yeast purified VHH fragments could be 
overcome by in situ production of the toxin neutralizing VHH fragments, the hamster 
protection model was repeated with engineered Lactobacillus expressing toxin 
neutralizing VHH. With the yeast purified VHH fragments failing to provide protection 
at concentrations that exceeds what could likely be achieved by L paracasei BL23 
secreting VHH fragments, it was decided to focus on toxin neutralization through a cell 
wall anchored display. Two strains of Lactobacillus displaying VHH fragments binding 
to non-overlapping epitopes (VHH-B2 and VHH-G3) were used in combination. 
Neutralization was tested in a prophylactic hamster protection model receiving a 
combined dose containing 5x109 CFU of each of the two Lactobacillus strains, KKA413 
and KKA416, twice daily for the duration of the experiment. 
For the groups receiving spores only or treated with a non-expressing strain of L. 
paracasei BL23, the course of infection for all animals was brief with the hamsters 
succumbing to the infection within 24 hours, with vegetative C. difficile being detected 
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in their stool samples. For the hamsters treated orally with the two engineered strains of 
L. paracasei BL23 displaying VHH-B2 and VHH-G3, a delay in development of 
infection and partial protection against killing were on the contrary observed  (p<0.05). 
Fifty percent of the hamsters in this group also survived until termination of the 
experiment at day 5 and showed either no damage or limited inflammation of the 
colonic mucosa despite having been colonized with C. difficile for up to 4 days. The 
complete absence or very limited mucosal damage in the hamsters despite having been 
colonized with C. difficile is significant, considering the rapid progression of the disease 
and the extensive damage to the colonic mucosa seen in C. difficile infections in 
hamsters. These results again suggest that the binding of the toxin to the cell wall 
displayed VHH fragments has a potential to efficiently neutralize the cytotoxic effects of 
toxin B. 
That the hamsters receiving the Lactobacillus displaying the toxin neutralizing VHH 
conferred a protective effect in the hamster model when the yeast purified VHH 
fragments failed to have an effect, raises interesting questions. The dose of VHH 
administered to hamsters was 100-fold lower when using engineered lactobacilli 
compared to the purified VHH. Several non-mutually exclusive possibilities may 
explain why cell wall anchored expression of the VHH could be advantageous compared 
to the yeast purified VHH. The anchoring of the VHH on the surface of the 
Lactobacillus would hugely increase the footprint of the VHH when bound to the toxin 
and make a larger part of the receptor binding domain inaccessible for binding to the 
receptor. Likewise, the bound toxin would be less free to diffuse in the gastrointestinal 
tract when immobilized on the cell wall of the Lactobacillus and the close proximity of 
the VHH molecules on the cell wall could provide an avidity effect. The use of a 
mixture of two Lactobacillus expressing VHH antibody fragments binding two different 
epitopes could also contribute to increase avidity, promote agglutination and clearance 
of the toxins. Possible VHH proteolysis might also be overcome by the direct in situ 
production of the VHH fragment in the colon where the VHH would be replenished as 
long as the lactobacilli were growing vegetatively. 
This study also seems to confirm a trend when using Lactobacillus for delivery of 
passive immunity where several studies have shown protective effect using anchored 
constructs in vivo (40, 41, 47, 50, 51). It is possible that anchored delivery of antibody 
binding domains is more effective for reasons outlined above but it could also be an 
artifact of the models used. When administering the engineered lactobacilli orally, the 
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supernatant containing the secreted antibody fragments are removed whereas the cell 
wall displayed are maintained on the surface of the lactobacilli. This gives an advantage 
when administering lactobacilli with cell wall displayed antibody fragments as they 
offer immediate protection whereas the protective effect of the secreted constructs 
require de novo production of the antibody fragments. In the describe studies, 
expression promoters that have been characterized for in vitro production have been 
used and though we expect them to be active in vivo their expression levels remains to 
be determined. Work has been undertaken to identifying promoters activated in the 
gastrointestinal tract and future expression constructs could likely be based on these 
(22). 
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5  CONCLUSIONS 
 
The aim of this thesis has been to explore the possibilities for using engineered 
lactobacilli for delivery of passive immunity against pathogenic bacteria in the 
gastrointestinal tract. The conclusions drawn from the individual papers in the thesis are: 
 
1. From a collection of lactobacilli, five human intestinal Lactobacillus strains 
were found to have properties required for a potential probiotic, suggesting 
that they would be suitable as vectors for delivery of passive immunity in 
the gastrointestinal tract. (Paper I) 
 
 
2. An integrative stable food grade expression system could be constructed 
based on the expression frame work of the apf gene of Lactobacillus 
crispatus. Furthermore, when expressing an anti-rotavirus VHH, the 
integrative expression system was equally protective as a plasmid based 
system in providing protection against rotavirus in a mouse pup model of 
infection.(Paper II) 
 
 
3. Expression of a high affinity anti-anthrax PA scFv by engineered L. 
paracasei BL23 can provide in situ protection against anthrax lethal toxin 
in the gastrointestinal tract. (Paper III) 
 
 
4. L. paracasei BL23 engineered for expression of a cell wall anchored anti-
toxin B VHH could significantly delay and partly protect against a lethal 
challenge with  spores of a toxin A-B+ strain of Clostridium difficile. (Paper 
IV) 
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6 FURTHER PERSPECTIVES 
 
The presented work has described the progress towards utilizing Lactobacillus for 
delivering passive immunity against gastrointestinal pathogens with a focus on the toxin 
producing pathogen C. difficile. It is the first example describing engineering lactobacilli 
for providing direct in situ toxin neutralization to prevent the cytotoxic effect of a toxin 
producing pathogen. Further work still needs to be carried out to bring this strategy to a 
stage where it can potentially be used as a supplement to the existing treatments against 
C. difficile infections. In the longer perspective there are also several other strategies that 
can be applied using engineered Lactobacillus for targeting C. difficile or other 
gastrointestinal pathogens. 
For the current strategy to be relevant in a clinical setting, neutralization against toxin A 
will likely also be needed to achieve complete protection against CDI (116, 180). In the 
current study we were unsuccessful in isolating a neutralizing anti-toxin A VHH despite 
a high toxin neutralizing serum titer and extensive panning of the phage library. 
However, other studies have shown that it is possible to isolate toxin A neutralizing 
VHH (232) but it could potentially require another immunization strategy, using either 
the receptor binding domain of toxin A or non-inactivated toxin A. 
As stated previously, chromosomal integration of the expression cassettes, removal of 
non-food grade DNA and inclusion of a containment system is today more or less a 
prerequisite for therapeutic application of engineered strains of Lactobacillus. This 
technology is currently available and can be easily adapted for the expression of VHH, 
as shown in paper II. 
For optimal delivery of the VHH in the gastrointestinal tract, a strain with the ability to 
colonize for a prolonged period of time could potentially give a better and more durable 
protective effect. In the current study, we have used L. paracasei BL23 as a vector for 
delivery of the anti-toxin VHH. This is a laboratory strain that has been widely applied 
for expression of heterologous proteins due to its ease of manipulation. It has been 
connected with both probiotic effect (238, 239), adhesion to the mucus membrane (240) 
and shown to colonize the gastrointestinal tract in mice (241). However, regarding the 
ability to persist in the human gastrointestinal tract, there are other strains with more 
well documented colonizing characteristics that could be used for production of the 
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VHH, like L. rhamnosus GG (242). Bifidobacteria constitutes another group of 
gastrointestinal bacteria that could be utilized for optimizing the therapeutic delivery, 
being more abundant than Lactobacillus in the gastrointestinal tract and with higher 
numbers in the colon where C. difficile colonizes (243, 244). The tools for engineering 
of Bifidobacteria are steadily improving and engineering for therapeutic purposes are 
becoming a possibility. 
In the current study, the anti-toxin VHH were raised against toxin A and B from the C. 
difficile VPI10436 strain. To ensure the best protective effect, either VHH with a broad 
toxin neutralizing activity against several toxinotypes should be selected or alternatively, 
multiple toxin neutralizing VHH should be used in combination. From a clinical point of 
view, VHH neutralizing the toxins from the hypervirulent PCR ribotype 027 strain 
would be especially relevant for delivering passive immunity. 
The two most likely applications for engineered Lactobacillus as a mean to delivering 
passive immunity against CDI would be either prophylactic treatment or treatment 
against recurrent infections. Prophylactic treatment could be used for patients belonging 
to defined risk groups for contracting CDI prior to scheduled hospitalization. This 
treatment would ideally start before or at the time of hospitalization and continue 
throughout the stay. Treatment against recurrent infections could likewise be based on a 
predefined risk profile for contracting re-current CDI and given as follow up treatment 
once antibiotic treatment is terminated. 
In our work we have directly targeted the two dominant virulence factors, toxin A and 
toxin B, to obtain the most significant effect. Several other approaches to engineering of 
Lactobacillus could also be used to target C. difficile to prevent the onset of CDAD 
either used on its own or in combination with strains of Lactobacillus producing toxin 
neutralizing VHH. 
Blocking of adhesion 
Expression of antibody fragments against C. difficile cell surface proteins (245) could be 
used to prevent the adhesion of C. difficile to the mucosa. Expressed as cell wall 
anchored VHH in Lactobacillus, they could both prevent adhesion of C. difficile to the 
mucosa and, possibly   even form large aggregates that would promote clearance of the 
bacteria from the gastrointestinal tract. 
Utilizing phage endolysins 
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Endolysins are phage encoded enzymes that towards the end of the lytic cycle are 
produced together with a holin to release the assembled phage particles by lysis of the 
bacteria. The holing forms large pore structures in the inner cell wall giving the 
endolysin access to reach and degrade the peptidoglycan layer, leading to lysis of the 
cell. The endolysin is a two domain protein with a C-terminal binding domain 
responsible for the binding to the peptidoglycan and an N-terminal catalytic domain 
responsible for the cleavage of the peptidoglycan bonds. They are to a wide extend, 
species or subspecies specific with the specificity being defined by the binding domain. 
Supplied externally, they can target Gram-positive bacteria directly without the need for 
the holin due to the lack of an outer membrane in Gram-positive bacteria. An endolysin 
cloned from a C. difficile bacteriophage produced and secreted from Lactobacillus could 
thus be used to directly target and lyse C. difficile in the gastrointestinal tract.  
Inhibiting the growth of C. difficile by production of bacteriocins  
Bacteriocins are produced by bacteria to prevent the growth of closely related species. 
Engineering of Lactobacillus for expression of bacteriocins could help to prevent the 
outgrowth and colonization of C. difficile in the gastrointestinal tract in individuals 
where the indigenous flora is damaged by antibiotic use. 
Toxin receptor blockage 
As well as neutralizing the toxins with Lactobacillus produced VHH, the toxin binding 
receptor could be targeted by expressing the binding domains or peptides containing the 
binding epitopes of the toxins. It has previously been shown that the C-terminal receptor 
binding domain from toxin A can effectively compete for binding to the toxin receptor 
and prevent the cytotoxicity of toxin A (235). This strategy would be difficult to 
combine with the expression of toxin neutralizing VHH and would need to stand alone 
or be combined with another approach. 
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